NEW YORK (GenomeWeb News) - Silence Therapeutics and Quark Pharmaceuticals this week announced an expansion of an existing technology licensing agreement that provided Quark with access to Silence Therapeutics’ AtuRNAi siRNA technology.

 

Silence Therapeutics said that the initial license and option agreement, signed in 2005, resulted in the development of an AtuRNAi-based compound, RTP801i, which Quark licensed to Pfizer in 2006. The compound is currently in clinical trials as a treatment for macular degeneration.